C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 121 filers reported holding C4 THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,887 | -31.8% | 56,391 | +0.9% | 0.00% | – |
| Q2 2023 | $153,753 | -29.5% | 55,910 | -19.5% | 0.00% | – |
| Q1 2023 | $218,101 | +127.8% | 69,459 | +328.1% | 0.00% | – |
| Q4 2022 | $95,733 | -32.6% | 16,226 | -0.2% | 0.00% | – |
| Q3 2022 | $142,000 | +35.2% | 16,256 | +17.3% | 0.00% | – |
| Q2 2022 | $105,000 | -96.9% | 13,855 | -90.0% | 0.00% | -100.0% |
| Q1 2022 | $3,358,000 | -77.5% | 138,412 | -70.2% | 0.00% | -75.0% |
| Q4 2021 | $14,948,000 | -28.9% | 464,202 | -1.3% | 0.00% | -20.0% |
| Q3 2021 | $21,023,000 | +18.4% | 470,523 | +0.2% | 0.01% | +25.0% |
| Q2 2021 | $17,761,000 | -21.2% | 469,395 | -23.0% | 0.00% | -33.3% |
| Q1 2021 | $22,553,000 | +126.5% | 609,719 | +102.9% | 0.01% | +100.0% |
| Q4 2020 | $9,957,000 | – | 300,542 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |